| Accession |
PRJCA013528 |
| Title |
Amplification of chromosome 11q13 associated with primary resistance to PD-1 blockade in unresectable hepatocellular carcinoma |
| Relevance |
Medical |
| Data types |
Targeted Locus (Loci)
|
| Organisms |
Homo sapiens
|
| Description |
A total of 62 HCC patients who underwent next-generation sequencing were retrospectively included in our department for this study. PD-1 inhibitors intervention (PD-1Ab) group and nonPD-1Ab group included 20 and 13 patients, respectively. Chromosome 11q13 amplification (Amp11q13) was the most common copy number variation in our cohort. Fifteen patients harbored Amp11q13 in our dataset. Des-γ-carboxy- prothrombin (DCP), albumin (ALB), tumor number and portal vein tumor thrombus (PVTT) were different between the Amp11q13 group and the nonAmp11q13 group. In the PD-1Ab group, the proportion of primary resistance in patients with Amp11q13 was significantly higher than that in patients with nonAmp11q13. In the PD-1Ab group, the median progression-free survival (PFS) was 1.5 months in Amp11q13 patients vs 16.2 months in non-Amp11q13 patients. HCC patients with Amp11q13 are less likely to benefit from PD-1 blockade therapies. These findings may help guide the use of immunotherapy for HCC in routine clinical practice. |
| Sample scope |
Multiisolate |
| Release date |
2022-11-28 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 37056769
|
Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma
|
Frontiers in Immunology
|
10.3389/fimmu.2023.1116057
|
2023
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Dongyu
Liu (dongyu.liu@3dmedcare.com)
|
| Organization |
3D Medicines Inc. |
| Submission date |
2022-11-28 |
